Produktsname: | (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9, 11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5, 12-dione |
CAS Registry Number: | 23214-92-8 |
EINECS: | 245-495-6 |
Synonyme: |
Adriamycin; Adriablastin; Doxil; Doxorubicinum; Adriblastin; Doxorubicine; Adriblastina; Myocet;(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9, 11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5, 12-dione; Rubex; |
Molecular Structure: | |
Molecular Formula: | C27H29NO11 |
Molecular Weight: | 543.51926 |
Dichte: | 1.61 g/cm3 |
Boiling Point: | RELATIVE DENSITY |
Schmelzpunkt: | 205℃ |
Flash Point: | 443.8 °C |
Brechungsindex: | 1.709 |
S-Sätze: | Confirmed carcinogen with experimental carcinogenic, neoplastigenic, and tumorigenic data. Poison by intraperitoneal, subcutaneous, parenteral, and intravenous routes. Human systemic effects by intravenous route: cardiac myopathy including infarction, nausea or vomiting, and effects on the hair. An experimental teratogen. Other experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of NOx and HCl. |
Gefahrensymbole: | UN NO. |